Yi-Tao He1, Bing-Shan Tang1, Zhi-Li Cai1, Si-Ling Zeng1, Xin Jiang2, Yi Guo3. 1. Department of Neurology, The Shenzhen People's Hospital, Shenzhen, China; Department of Neurology, The Jinan university medical school second affiliated hospital, Shenzhen, China. 2. Department of Gerontology, The Shenzhen People's Hospital, Shenzhen, China. 3. Department of Neurology, The Shenzhen People's Hospital, Shenzhen, China; Department of Neurology, The Jinan university medical school second affiliated hospital, Shenzhen, China. Electronic address: xuanyi_guo@163.com.
Abstract
OBJECTIVE: We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke. METHODS: In this prospective randomized controlled single-blind clinical study in China, eligible patients afflicted with ischemic stroke were randomized into control and treatment groups. Patients in the treatment group received fluoxetine in addition to the basic therapies in the control group over a period of 90 days. The follow-up period was 180 days. We evaluated the effects of fluoxetine on the National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) scoreafter ischemic stroke through single- and multiple-factor analysis. RESULTS: The mean NIHSS score on day 180 after treatment was significantly lower in the treatment group than in the control group (P = .009). The mean BI scores on days 90 and 180 were significantly higher in the treatment group (P = .026) than in the control group (P = .011). The improvements in the NIHSS and BI scores on days 90 and 180 compared with baseline in the treatment group were all significantly greater than that in the control group (P = .033, P = .013, P = .013, P = .019, respectively). Treatment with fluoxetine was an independent factor affecting the NIHSS and BI scores on day 180 after treatment. CONCLUSION: Treatment with fluoxetine for 90 days after ischemic stroke can improve the long-term neural functional outcomes.
RCT Entities:
OBJECTIVE: We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke. METHODS: In this prospective randomized controlled single-blind clinical study in China, eligible patients afflicted with ischemic stroke were randomized into control and treatment groups. Patients in the treatment group received fluoxetine in addition to the basic therapies in the control group over a period of 90 days. The follow-up period was 180 days. We evaluated the effects of fluoxetine on the National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score after ischemic stroke through single- and multiple-factor analysis. RESULTS: The mean NIHSS score on day 180 after treatment was significantly lower in the treatment group than in the control group (P = .009). The mean BI scores on days 90 and 180 were significantly higher in the treatment group (P = .026) than in the control group (P = .011). The improvements in the NIHSS and BI scores on days 90 and 180 compared with baseline in the treatment group were all significantly greater than that in the control group (P = .033, P = .013, P = .013, P = .019, respectively). Treatment with fluoxetine was an independent factor affecting the NIHSS and BI scores on day 180 after treatment. CONCLUSION: Treatment with fluoxetine for 90 days after ischemic stroke can improve the long-term neural functional outcomes.